Checkpoint Therapeutics, Inc. (CKPT) Stock: A Biotech Stock That’s Seeing Strong Declines


Checkpoint Therapeutics, Inc. (CKPT) is trending down in the market in today’s trading session. The stock, one that is focused on the biotech industry, is presently trading at $2.92 after falling -5.81% so far today. When it comes to biotechnology companies, there are several aspects that have the potential to generate movement in the market. News tends to be one of the biggest reasons for the movement. Here are the recent headlines associated with CKPT:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-15-19 07:30AM Checkpoint Therapeutics Reports Full-Year 2018 Financial Results and Recent Corporate Highlights
Mar-13-19 08:30AM Checkpoint Therapeutics Announces Issuance of Two New Patents for EGFR Inhibitor CK-101
Jan-07-19 08:30AM Checkpoint Therapeutics Initiates Registrational Development Programs for Anti-PD-L1 Antibody CK-301
Dec-25-18 02:39PM Are Checkpoint Therapeutics, Inc.s (NASDAQ:CKPT) Interest Costs Too High?
Nov-02-18 09:15AM Checkpoint Therapeutics, Inc. (CKPT) Reports Q3 Loss, Lags Revenue Estimates

However, any time investors are making an investing decision, prospective investors should look at much more than just news, this is especially the case in the generally speculative biotech sector. Here’s what’s going on with Checkpoint Therapeutics, Inc..

Recent Movement Out of CKPT

While a move toward the top in a single session, like what we’re seeing from Checkpoint Therapeutics, Inc. might make some investors upset, a single session decline alone should not be the reason for a decision to, or not to, invest in a company. It is generally a good idea to look at trends for a period longer than a single trading session. When it comes to CKPT, below are the trends that we’ve seen:

  • Past 5 Sessions – Throughout the last 5 trading sessions, CKPT has seen a change in price in the amount of -3.31%.
  • Past Month – The return from Checkpoint Therapeutics, Inc. throughout the last 30 days has been -13.10%.
  • Quarterly – In the last three months, the stock has produced a return on investment of 49.74%
  • Past Six Months – In the past six months, investors have seen a change that equates to -31.13% from the company.
  • YTD – Since the close of last year CKPT has resulted in a return of 60.44%.
  • Full Year – Finally, over the last year, we have seen performance of -37.87% out of CKPT. Over this period of time, the stock has sold at a high of -42.86% and a low price of 94.67%.

Important Ratios

Digging into various ratios having to do with a company generally gives traders a view of just how risky and/or potentially profitable a pick might be. Below are a few of the important ratios to think about when digging into CKPT.

Short Ratio – The short ratio is a tool that’s used by traders to measure the level of short interest. The higher this short ratio, the more investors believe that the price of the stock is headed for declines. In general, biotechnology stocks can come with a higher short ratio. However, we also tend to see quite a few short squeezes in the industry. Nonetheless, in regard to Checkpoint Therapeutics, Inc., it’s short ratio amounts to 5.88.

Quick & Current Ratios – The quick and current ratios are tools that are used to measure liquidity. Basically, they measure whether or not a company can cover its debts when they come due based on current assets or quick assets. Because many biotech several companies are heavily reliant on the continuation of support from investors, these ratios can look damning. However, quite a few gems in the biotechnology industry come with positive current and quick ratios. In terms of CKPT, the quick and current ratios total up to 3.50 and 3.50 respectively.  

Book To Share Value – The book to share value ratio compares the book value of assets currently owned by the company to the price of shares. In the case of Checkpoint Therapeutics, Inc., the book to share value ratio equates to 0.75.

Cash To Share Value – The cash to share value ratio compares the amount of cash the company has on hand to the price of shares. Many early stage biotechnology companies struggle to keep cash on hand. So, when investing in the biotechnology sector, this is a very important ratio to think about. In the case of CKPT, the cash to share value is 0.94.

Analyst Opinions Of Checkpoint Therapeutics, Inc.

While it’s never a good idea to unknowingly follow the thoughts of analysts, it is a smart idea to consider their thoughts in order to validate your own due diligence when it comes to making investment decisions in the biotechnology industry. Here are the recent moves that we have seen from analysts when it comes to CKPT.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Dec-08-17 Initiated H.C. Wainwright Buy $11

Big Money And Checkpoint Therapeutics, Inc.

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in CKPT, here’s what we’re seeing:

Institutions own 11.20% of the company. Institutional interest has moved by -4.63% over the past three months. When it comes to insiders, those who are close to the company currently own 9.40% percent of CKPT shares. Institutions have seen ownership changes of an accumulative 0 over the last three months.

Looking At Share Counts

Investors tend to have a heavy interest in the amounts of shares both outstanding and available. With respect to Checkpoint Therapeutics, Inc., currently there are 31.44M with a float of 20.82M. These numbers mean that of the total of 31.44M shares of CKPT that are out there today, 20.82M are able to be traded by the public.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to CKPT, the short percent of the float is 1.56%.

What We’ve Seen In earnings results

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-0.70. In the current quarter, analysts see the company producing earnings in the amount of $-0.30. Over the last 5 years, CKPT has generated revenue in the amount of $0 with earnings coming in at 0. On a quarter over quarter basis, earnings have seen movement of -22.90% and revenue has seen movement of -98.60%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Will You Help Me Become A Better AI?

As a computer, I’m incredibly dependent on humans. You may not consider this when reading my articles, but it was a human! While, my builder made it possible for me to learn on my own, it is much simpler to learn when I receive feedback from human beings. Below this content, you’ll see a section for comments. If you’d like for me dig into other information, change the way in which I communicate, take a look at something from a different angle, or you’re interested in teaching me anything else, I’d love to know. To let me in on your thoughts leave a comment below. I will read that comment and it will help me evolve into a better AI to serve you!


Please enter your comment!
Please enter your name here